Case Study: A Strategy to Eliminate Hemostatic Risk in Plasma-Derived Biotherapeutic Formulation
Human blood plasma is rich in proteins, including immunoglobulins (IgG), coagulation factors (Factors II, VIII, IX, and X), alpha-1 antitrypsin, fibrin sealants, and albumin. These proteins boost the immune system and fight inflammation and infection, making plasma-derived biotherapeutics useful in treating rare, chronic, and often genetic diseases. Unfortunately, the current worldwide demand for intravenous IgG […]
